Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01053988 · ClinicalTrials.gov registry record · Phase 3
A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by GlaxoSmithKline.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,031
- Enrollment target
NCT01053988 is a Phase 3 study that has completed, run by GlaxoSmithKline. The registered enrollment target is 1,031 participants.
The verdict
NCT01053988, a Phase 3 study, has completed, sponsored by GlaxoSmithKline.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,031 participants
- Enrollment target
Study Summary
The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
Interventions
- DRUG Placebo
- DRUG FF Inhalation Powder
- DRUG FF/GW642444 Inhalation Powder
- DRUG GW642444 Inhalation Powder
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,031 participants |
| Start Date | 2009-10-05 |
| Est. Completion | 2011-04-14 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01053988
The ClinicalTrials.gov registry entry for NCT01053988 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,031 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Placebo is the first listed.
NCT01053988 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01053988 about?
NCT01053988 is a clinical study titled "A 6-month Study to Evaluate the Efficacy and Safety of Fluticasone Furoate (FF)/GW642444 Inhalation Powder in Subjects With Chronic Obstructive Pulmonary Disease (COPD)". The Purpose of this study is to assess the efficacy and safety of two strengths of the FF/GW642444 Inhalation Powder in subjects with chronic obstructive pulmonary disease (COPD)
What is the current status of trial NCT01053988?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,031 participants. The study started on 2009-10-05. Estimated completion is 2011-04-14.
What interventions are being tested in trial NCT01053988?
The interventions under investigation include: Placebo (DRUG), FF Inhalation Powder (DRUG), FF/GW642444 Inhalation Powder (DRUG), GW642444 Inhalation Powder (DRUG).
Who is sponsoring clinical trial NCT01053988?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.